OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology International is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
The safety profile of endoscopic variceal ligation in patients with esophageal varices	110
HBV in pregnancy: time to consider tenofovir alafenamide (TAF)	95
Metabolically healthy obese and MAFLD: does weight status alone matter?	80
Platelets in acute liver failure: an innocent bystander or instigator?	78
Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial	63
Diagnosis of significant liver fibrosis in patients with chronic hepatitis B using a deep learning-based data integration network	61
Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk	60
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD	57
‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure	55
Good outcomes of living donor liver transplant in primary sclerosing cholangitis: an experience from North India	43
Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression	43
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease	43
Antibiotic prophylaxis in upper gastrointestinal bleeding with Child-Pugh A cirrhosis: need for objective infection markers and broader studies	43
The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes	42
Effect of microbiota metabolites on the progression of chronic hepatitis B virus infection	41
Methodological reflections on vasoconstrictor use in refractory ascites: bridging trial rigor and real-world relevance	40
Pure laparoscopic versus open left lateral hepatectomy in pediatric living donor liver transplantation: a review and meta-analysis	37
Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study	37
Response to: “Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues”	36
Antioxidant, selenium and risk of nonalcoholic fatty liver disease, more than causality	35
Predictive value of soluble PD-1 for HBsAg loss in HbeAg-negative patients with chronic hepatitis B: results from a prospective study	34
Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma	34
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets	33
Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection	32
Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis	32

Commentary on “Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled t	32
Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy	31
Long-term morbidity and mortality in 2-year hepatoblastoma survivors treated with SIOPEL risk-adapted strategies	31
Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria	30
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis	29
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis	29
Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis	29